News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
News AbbVie builds the case for ovarian cancer drug Elahere AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.
News Sutro puts lead ADC on hold, cuts staff and changes CEO Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.
Oncology Harnessing IL-12: Immunotherapy research advances may enhanc... While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer recurrence, more effective disease maintenance strategies, more preci
News MSD gets first positive trial of Keytruda/Lynparza combo After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
R&D Sponsored Turning recruitment potential into enrolment reality In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
